Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: Results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages 287-294

  Elewski, B E ^a   Ghannoum, M A ^b   Mayser, P ^c   Gupta, A K ^d   Korting, H C ^e   Shouey, R J ^f   Baker, D R ^g   Rich, P A ^h   Ling, M ⁱ   Hugot, S ^j   Damaj, B ^k   Nyirady, J ^j   Thangavelu, K ^j   Notter, M ^j   Parneix Spake, A ^j   Sigurgeirsson, B ^l  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF MUNICH   (Germany)

^f Harrisonburg Foot Clinic   (United States)

^g Allergy Asthma and Dermatology Research Center LLC   (United States)

^h Oregon Dermatology and Research Center   (United States)

ⁱ MedaPhase Inc   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k NexMed (USA) Inc   (United States)

^l UNIVERSITY OF ICELAND   (Iceland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; PLACEBO; TERBINAFINE;

ADOLESCENT; AGED; ARTICLE; BACKACHE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MYCOLOGY; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIMULATION; SINUSITIS; TINEA PEDIS; TOENAIL ONYCHOMYCOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; NAPHTHALENES; ONYCHOMYCOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84874104842     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04373.x     Document Type: Article

References (48)

1. Roberts DT,. Prevalence of derm atophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126: 23-27.
2. Elewski BE, Charif MA,. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172-1173.
3. Sais G, Jucglà A, Peyrí J,. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758-761.
4. Heikkilä H, Stubb S,. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703.
5. Sigurgeirsson B, Steingrímsson O, Sveinsdóttir S,. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002; 82: 467-469.
6. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC,. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada-a multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783-787.
7. Svejgaard EL, Nilsson J,. Onychomycosis in Denmark: prevalence of fungal nailinfection in general practice. Mycoses 2004; 47: 131-135.
8. Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139: 665-671.
9. Pierard GE, Pierard-Franchimont C,. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 2005; 48: 339-342.
10. Elewski BE,. Onychomycosis treatment, quality of life, and economic issues. Am J Clin Dermatol 2000; 1: 19-26.
11. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702-704.
12. Turner RR,., Testa MA,. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res 2000; 9: 39-53.
13. Baran R, Kaoukhov A,. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19: 21-29.
14. Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007; 157: 149-157.
15. Prescrire R,. Fungal nail infections: diagnosis and management. Prescrire Int 2009; 18: 26-30.
16. Finch JJ, Warshaw EM,. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007; 20: 31-46.
17. Kumar S, Kimball AB,. New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs 2009; 18: 727-734.
18. Paus RPS, Sundberg JP,. In, Bonognia JL, Jorizzo JL, eds. Biology of Hair and Nails. Dermatology, 2nd edn. Elsevier, Amsterdam, 2008: 965-986.
19. Roberts DT,. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 (Suppl 39): 23-27.
20. Roberts DT,. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 (Suppl 56): 1-4.
21. Schwartz RA, Janniger CK,. Onychomycosis. Cutis 1996; 57: 67-74.
22. Gupta AK, Fleckman P, Baran R,. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43: S70-S80.
23. Jaiswal A, Sharma RP, Garg AP,. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2007; 73: 393-396.
24. Petranyi G, Ryder NS, Stutz A,. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239-1241.
25. Gupta AK, Ryder JE, Johnson AM,. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-544.
26. Schafer-Korting M, Schoellmann C, Korting HC,. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol 2008; 21: 203-210.
27. Ghannoum MA, Wraith LA, Cai B, Nyirady J, Isham N,. Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial. Br J Dermatol 2008; 159: 711-713.
28. Ghannoum MA, Long L, Pfister WR,. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009; 52: 35-43.
29. Gupta A, Robbins J, Pfister W,. Terbinafine nail solution is highly effective for the treatment of onychomycosis: a double-blind, randomized, dose-finding clinical trial. Paper presented at: Annual Scientific Meeting of Am Podiatr Med Assoc 2008; July 24-27; Honolulu, HI, USA.
30. Burkhart CN, Burkhart CG, Gupta AK,. Dermatophytoma: recalcitrance to treatment because of existence of fungal biofilm. J Am Acad Dermatol 2002; 47: 629-631.
31. Ghannoum MA, Chaturvedi V, Espinel-Ingroff A, et al. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol 2004; 42: 2977-2979.
32. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd edn. CLSI, Wayne, PA, 2008. CLSI document M38-A2 [ISBN 1-56238-668-9].
33. Bauer P, Rohmel J,. An adaptive method for establishing a dose-response relationship. Stat Med 1995; 14: 1595-1607.
34. Gupta AK, Baran R,. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000; 43: S96-S102.
35. Reinel D,. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992; 184 (Suppl 1): 21-24.
36. Lauharanta J,. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 (Suppl 1): 41-43.
37. Claveau J, Vender RB, Gupta AK,. Multitherapy approach to onychomycosis therapy. J Cutan Med Surg 2006; 10 (Suppl 2): S44-S47.
38. Poulin Y, Thomas R, Gupta AK,. Brief treatment guide for onychomycosis. J Cutan Med Surg 2006; 10 (Suppl 2): S39-S43.
39. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-308.
40. De Cuyper C, Hindryckx PH,. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141 (Suppl 56): 15-20.
41. Werschler WP, Bondar G, Armstrong D,. Assessing treatment outcomes in toenail onychomycosis clinical trials. Am J Clin Dermatol 2004; 5: 145-152.
42. Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007; 56: 939-944.
43. Hay RJ,. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001; 145 (Suppl 60): 3-8.
44. Sigurgeirsson B,. Prognostic factors for cure following treatment of onychomycosis. J Eur Acad Dermatol Venereol 2010; 24: 679-684.
45. Epstein E,. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 1998; 134: 1551-1554.
46. Gupta AK, Lynch LE, Kogan N, Cooper EA,. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 256-262.
47. Sigurgeirsson B, Elewski BE, Rich PA, et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat 2006; 17: 38-44.
48. Elewski BE,. A full "cure" for onychomycosis is not always possible. Arch Dermatol 1999; 135: 852-853.